GLP-3 RT (10mg)
Műszaki specifikációk
| Tisztaság (HPLC) | ≥97% (HPLC) |
| CAS szám | 2381089-83-2 |
| Forma | White lyophilized powder |
| Tárolás | -20°C |
| Szekvencia | Modified triple incretin agonist |
| Molekulatömeg | 4,803.56 g/mol |
| Sóforma | Acetate |
| Oldhatóság | Soluble in aqueous buffer |
GLP-3 RT (10mg)
EUR listaár · HU, SK, CZ, PL
- Eurozone (EUR)252,00 EUR
- Magyarország (HU)252,00 EUR≈ 100 800 Ft
- Szlovákia (SK)252,00 EUR
- Csehország (CZ)252,00 EUR≈ 6 300 Kč
- Lengyelország (PL)252,00 EUR≈ 1071,00 zł
Ugyanaz az EUR listaár a szállítás esetén Magyarországra, Szlovákiába, Csehországba és Lengyelországba. Fizetés EUR-ban.
A HUF/CZK/PLN összegek tájékoztató jellegűek (EUR-ból átszámítva); Szlovákia az eurót használja. Árfolyamok közelítők. Fizetés EUR-ban.
Retatrutid — hármas inkretin agonista (GLP-1R, GIPR, GCGR); anyagcsere- és testsúly–kutatási publikációk fókuszában. Liofilizátum −20 °C-on, rázkódásmentesen tárolandó. Kizárólag megfelelő engedéllyel rendelkező laborok számára, RUO.
Kizárólag laboratóriumi kutatásra.
Nem emberi fogyasztásra, állatorvosi vagy diagnosztikai felhasználásra.
From the Peptide Explorer
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Key Mechanisms
- ›GIP receptor agonism
- ›GLP-1 receptor agonism
- ›Glucagon receptor agonism (energy expenditure)
- ›Hepatic lipid metabolism enhancement
- ›Appetite suppression via CNS pathways
Primary Research Areas
- ›Obesity
- ›NASH
- ›Metabolic syndrome
- ›Triple-incretin signaling
- ›Energy expenditure
Key Research Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Overview
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Origin: Triple GIP/GLP-1/glucagon receptor agonist by Eli Lilly
Mechanism of Action
- GIP receptor agonism
- GLP-1 receptor agonism
- Glucagon receptor agonism (energy expenditure)
- Hepatic lipid metabolism enhancement
- Appetite suppression via CNS pathways
Primary Research Areas
- Obesity
- NASH
- Metabolic syndrome
- Triple-incretin signaling
- Energy expenditure
Key Published Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
2-8°C
Important Notice
Retatrutide (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Kutatási specifikációk
Synthesized for strict analytical consistency. Verified via HPLC/MS.Minőségi standardok megtekintése →
Kezelés és tárolás
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in aqueous buffer
Gyakori kérdések
What is GLP-3 RT (10mg)?▼
Is GLP-3 RT (10mg) intended for human consumption?▼
How do you verify purity and identity?▼
How should GLP-3 RT (10mg) be stored?▼
Do you provide a Certificate of Analysis (COA)?▼
What purity is GLP-3 RT (10mg)?▼
Verified Research Reviews
Reta is amazing
"really amazing compound and interesting "